Latest News About 2-Amino-3-Phosphonopropionic Acid

Here’s the latest I can share based on typical up-to-date sources.

• 2-Amino-3-phosphonopropionic acid (AP3) is commonly used as an antagonist of metabotropic glutamate receptors (mGluRs) in neuroscience research, with activity reported against several mGluR subtypes in various studies. It has been described as a tool to probe synaptic plasticity, including blocking LTD in hippocampal preparations in some reports.[1][3]
• Some sources indicate ongoing interest in AP3 and its derivatives for potential therapeutic angles related to glutamatergic signaling and neurodegenerative contexts, including investigations into mechanisms affecting amyloid precursor protein (APP) release in neurons under glutamatergic stimulation.[3][4]
• Pharmacological data such as inhibition constants (Ki) have been reported for related apoproteins or enantiomeric forms, highlighting activity differences among DL-AP3 and its enantiomers, though values vary across preparations and assay systems.[1]
• Public databases list AP3 with standard identifiers and provide basic physicochemical and pharmacological context; for example, DrugBank, HMDB, PubChem, and others host entries describing structure, predicted ADMET features, and general uses in research.[2][6][3]

If you’d like, I can compile a brief, source-by-source annotated crib sheet (with citations) or pull the most recent primary literature summaries on AP3’s receptor activity, LTD/LTP effects, and any Alzheimer’s-relevant findings. I can also look up current supplier availability and any new derivatives or analogs that have emerged in 2024–2026.

Would you like a focused literature brief on:

• AP3 as an mGluR antagonist and its effects on LTD/LTP?
• AP3’s links to APP processing and Alzheimer's-related hypotheses?
• Recent synthetic derivatives or clinical research directions?